In the 2018 update of the EORTC guidelines regarding blood classification and blood response in MF and SS, new recommendations for diagnosis included the detection of disease-specific changes such as increased CD4/CD8 ratio and loss of CD7 and CD26 surface markers using flow cytometry [12]. This evidence concerns the gene DPP4 and synovial sarcoma.